Entering the Russian market with reagents and test systems for laboratory diagnostics is impossible without state registration. Unlike complex equipment (e.g., CT scanners or ultrasound machines), reagent kits have their own specifics: the focus here is not on technical parameters but on analytical sensitivity, specificity, and reproducibility. Let’s walk through step by step what needs to be done to obtain marketing authorisation for a diagnostic kit in 2025–2026, and how this process differs from registering hardware devices.
What Is a Diagnostic Kit from a Legal Perspective?
Federal Law No. 323‑FZ classifies reagents, calibrators, control materials, and test systems as medical devices when they are used for in vitro diagnostics (outside the human body). Their primary action is not pharmacological, immunological, or metabolic – it is based on a chemical or biological reaction with a patient sample.
Registration grants the right to manufacture, import, and sell such kits in the Russian Federation and EAEU member states. Without it, the product is considered counterfeit – fines for legal entities can reach 2–3 million roubles, and in some cases criminal liability (Article 238.1 of the Criminal Code) applies. Moreover, paper certificates are no longer issued; registration is confirmed solely by an electronic entry in the Roszdravnadzor register.
New Rules from 2025: What Matters for Reagent Manufacturers
Since 1 March 2025, the Registration Rules approved by Government Resolution No. 1684 have been in force. For developers of diagnostic kits, the key changes are:
-
Faster “non‑clinical” procedures – if the kit already has proven analytical performance and does not require human trials, the review period is reduced to 31 days (previously up to 60).
-
Fully digital workflow – all applications, test reports, and expert opinions are submitted only via the Roszdravnadzor personal cabinet. Paper copies are no longer accepted.
-
Stricter requirements for clinical data – for kits that require human studies, clinics must upload raw data to the automated system within three working days after the trial is completed.
-
Extended transition period – until 1 September 2026, manufacturers can update information about their authorised representatives without penalties.
Note: for reagents already registered under the old rules (No. 1416), registration remains indefinite, but any changes (composition, packaging, intended use) can only be made under the new rules after 31 December 2026.
Risk Classification for Reagents: Not Always as Simple as It Seems
Although diagnostic kits are usually assigned to class 2a (moderate risk), the actual class may vary depending on the intended use:
-
Class 1 – simple buffer solutions, storage media for samples (minimal risk).
-
Class 2a – most commercial test systems for detecting infections, hormones, tumour markers (moderate risk, because an erroneous result affects treatment decisions).
-
Class 2b – reagents for blood donor screening, for diagnosing particularly dangerous infections (HIV, hepatitis) – here the risk is elevated.
-
Class 3 – kits for prenatal diagnosis or personalised therapy selection (high risk).
The class determines the scope of testing: for class 2a, analytical validation is sufficient; for classes 2b and 3, full clinical trials on representative patient cohorts are required.
Registration Stages: From Development to Registry Entry
The process for reagents consists of four logical blocks, each critical for success.
Block 1. Analytical Validation and Technical Documentation
Unlike equipment, where electrical safety and radiation are checked, here the main goal is to prove that the reagent consistently produces correct results under specified conditions. The following are developed:
-
technical specifications (TU) indicating composition, storage conditions, and shelf life;
-
instructions for use (assay procedure);
-
risk analysis file (FMEA analysis of possible operator errors and reagent failures);
-
analytical validation protocols: sensitivity, specificity, linear range, limits of detection.
All documents must be prepared in Russian, and units of measurement must comply with GOST standards.
Block 2. Testing in Accredited Centres
For classes 2a and above, three types of studies are mandatory:
-
Technical tests – verification of declared characteristics in a Roszdravnadzor laboratory or accredited organisation.
-
Toxicological studies – assessment of the safety of materials that come into contact with biological fluids (if the kit contains preservatives or stabilisers).
-
Clinical‑laboratory trials – comparison of results obtained with your kit against a reference method or a commercial analogue using clinical samples (serum, plasma, urine, etc.).
Important: for domestic manufacturers, a simplified scheme applies – if technical and toxicological tests are performed at VNIIIMT and clinical trials at federal medical research centres, the document review is conducted only once, without re‑examination after amendments. This saves 2–3 months overall.
Block 3. Submission of the Electronic Dossier
The document package is structured and submitted through the elk.Roszdravnadzor system. The applicant may be the manufacturer or its Russian authorised representative. The state fee is paid by bank transfer, and the receipt is attached to the application.
Block 4. Expert Review and Registry Entry
Roszdravnadzor conducts the review within 31 days (if no clinical trials) or up to 50 working days (if trials were performed). If the decision is positive, a unique entry is made in the state register – this is the official confirmation of registration. A paper certificate is issued only upon separate request, but the legally binding document is the registry record.
Specific Points Often Overlooked
When working with reagents, several aspects that do not arise for equipment registration should be considered:
-
Compatibility with analysers – your kit must work on specific instruments (e.g., PCR detectors or immunoassay platforms). The new rules require providing evidence of compatibility with devices from other manufacturers – this speeds up adoption and prevents market monopolisation.
-
Transport stability – for reagents, it is critical to specify temperature conditions and shelf life under real logistics conditions. This is included in the technical documentation and verified during testing.
-
Validation on Russian samples – clinical trials must be conducted on a population representative of the Russian Federation (epidemiological specifics). Foreign data are accepted only as supplementary evidence.
-
Composition changes – if you replace one reagent component, it is considered a substantial change and must be registered separately (timeline – 18 days under the new procedure).
Final Recommendations
Successful registration of a diagnostic kit is not a bureaucratic formality but a comprehensive set of scientifically sound evidence of its efficacy and safety. Errors in choosing the risk class, incorrectly drafted test protocols, or incomplete risk analysis can lead to refusal and wasted time.
Special caution is needed during the transition to the new Rules No. 1684: although they shorten timelines, they also introduce stricter reporting and mandatory digitalisation. It is better to entrust this process to professionals who stay up to date with all changes.
Elibrium offers full‑cycle support for registration of medical devices, including diagnostic kits and in vitro reagents. We help you:
-
determine the optimal risk class and testing strategy;
-
develop and translate documentation in accordance with current GOST and TR CU standards;
-
arrange technical, toxicological, and clinical‑laboratory tests in accredited centres;
-
prepare and submit the electronic dossier through the Roszdravnadzor system;
-
promptly respond to expert comments and obtain the registry entry in the shortest possible time.
Elibrium accompanies clients at every stage – from raw material analysis to post‑registration monitoring. We guarantee an individual approach, quality control at every step, and full transparency. By choosing us, you gain not just a service, but a reliable partner for bringing your diagnostic products to the Russian market.
